Breast Biopsy Needle Shortage: What the FDA and ACR Say Patients Should Ask About

If you were told you need a stereotactic breast biopsy and your appointment is delayed, it’s understandable to feel worried. You’re not powerless, though. The FDA and the American College of Radiology (ACR) have issued guidance aimed at reducing patient impact during a U.S. medical device supply disruption.

In plain terms: the FDA has said the stereotactic breast biopsy needle supply interruption is expected to last through the end of Q1 2027. The ACR offers practical strategies clinicians may use to mitigate shortages and communicate with patients.

What the FDA says about the shortage

In a June 16, 2026 letter to health care providers, the FDA described interruptions in the supply of stereotactic breast biopsy needles and said the agency expects the disruption to extend through the end of Q1 2027. The FDA also notes that, during shortages, clinical teams may need to adjust how they manage patients who are indicated for breast biopsy.

The FDA’s communication also references that this shortage is occurring alongside earlier manufacturer actions affecting some biopsy needle availability used in certain systems.

If you want a publicly tracked snapshot, the FDA maintains a Medical Device Shortages List that includes stereotactic breast biopsy needles and reflects the expected time window.

What the ACR says practices may do during shortages

The ACR’s mitigation guidance (updated June 16, 2026) is written for radiology and imaging teams, but it can help you know what to ask about. The ACR emphasizes:

Case prioritization: patients with more suspicious findings may be prioritized for biopsy when supply is limited.
Using alternatives when appropriate: teams may consider other diagnostic pathways (for example, when clinically appropriate, shifting some biopsies toward different guidance methods).
Short-interval follow-up when clinically suitable: for lower-suspicion situations, some patients may be managed with planned short-interval follow-up rather than immediate biopsy—when the clinician determines this is appropriate.
Needle and workflow conservation: practices may try to reduce waste and better match the limited supply to patients most likely to benefit urgently.
Patient communication and back-up plans: clear communication about delays and availability, including alternative sites when feasible.

Where biopsy fits after an abnormal mammogram

After an abnormal screening mammogram, clinicians typically use additional tests to determine next steps. The CDC explains that the diagnostic pathway can include diagnostic mammogram, breast ultrasound, and breast MRI, followed by biopsy when tissue diagnosis is needed.

Biopsy matters because it helps provide a more definitive diagnosis—information that can affect treatment planning if cancer is found.

“What if my biopsy is delayed?” What research suggests about distress

Waiting for diagnostic results can be emotionally difficult. A peer-reviewed study indexed in PubMed evaluated diagnostic delays in breast cancer patients and reported that longer time intervals between mammogram and biopsy were associated with distress measures in some domains.

Two important context points: the study was retrospective, and distress was assessed at an early evaluation time point—meaning distress may have started before the measured “delay.” The takeaway is not that every delay causes harm, but that uncertainty can be hard, and clinical decisions about timing can be influenced by triage and appropriateness.

A short checklist: questions to ask your care team now

Use this list during a call, appointment, or patient portal message. If you’re a caregiver, you can help by taking notes and asking for written instructions.

Is my biopsy planned specifically as stereotactic? If so, what determines my timing?
How is my case prioritized? Ask whether your finding is considered higher versus lower suspicion for biopsy during the shortage.
What delay should I expect at your facility? If supply is limited, ask for a best estimate and what would change that estimate.
What is the backup plan? For example, is an alternative diagnostic pathway or alternative scheduling site possible?
If biopsy is deferred, what happens instead? Ask what the planned next step is (such as a short-interval follow-up plan) and the exact timing.
Could my team switch to a different approach when clinically appropriate? Ask what alternatives exist for your specific imaging finding.
If I can’t make the new date, what should I do? Ask whether they can hold a spot, move you to another site, or adjust the plan.

When to contact someone urgently vs. wait for the scheduled plan

If you have been given specific pre-procedure instructions, follow them. Contact your clinician promptly (or seek urgent/emergency care if your care team has already advised this for certain symptoms) if you develop concerning symptoms after a biopsy, such as signs of infection or significant bleeding.

If your issue is delay due to the shortage, it’s usually reasonable to request clarification and a specific next step during normal business hours—using the questions above.

What remains uncertain

Even with national guidance, what you experience can vary by facility and by your clinical situation. Key uncertainties may include:

Local availability and scheduling: the shortage window may be months, but appointment timing depends on inventory and workflow.
Which alternatives are clinically feasible for your finding: imaging characteristics and clinical judgment drive what options are appropriate.
How teams prioritize: prioritization may differ from one practice to another, even within the same shortage period.

If you need a next step today, the most practical approach is to ask your care team how they’re applying FDA and ACR recommendations to your case and what backup options exist for timing and location.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.